Cryoablation des tumeurs mammaires : mise au point en 2024
Imagerie de la Femme, ISSN: 1776-9817, Vol: 34, Issue: 4, Page: 187-195
2024
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
La prise en charge du cancer du sein connaît une transformation significative depuis plusieurs décennies, marquée par une tendance à la désescalade thérapeutique. Cette évolution est soutenue par le vieillissement de la population, l’augmentation de l’espérance de vie et les progrès dans les méthodes de détection par imagerie sénologique, renforcées récemment par l’intégration des algorithmes d’intelligence artificielle. Les données définitives de l’essai ICE3, présentées lors du 25 e congrès annuel de l’American Society of Breast Surgery (ASBrS), en conjonction avec les publications récentes des essais intitulés LUMINA et SOUND, inaugurent une nouvelle phase dans la gestion des cancers du sein à faible risque dans une population ciblée, offrant une alternative à la chirurgie conventionnelle. Cet article explore les fondements de la cryoablation mammaire, en passant en revue les indications cliniques établies, les techniques de réalisation, ainsi que les principes de la cryo-immunologie. Breast cancer management has been undergoing significant transformations for decades, marked by a trend toward therapeutic de-escalation. This evolution is supported by the aging of the population, increased life expectancy, and advancements in detection methods using breast imaging, recently enhanced by the integration of artificial intelligence algorithms. The final results of the ICE3 trial, unveiled at the 25th annual congress of the American Society of Breast Surgery (ASBrS), along with recent publications from the LUMINA and SOUND trials, herald a new era in the management of low-risk breast cancers in a targeted population, offering an alternative to conventional surgery. This article explores the fundamentals of breast cryoablation, reviewing established clinical indications, execution techniques, and the principles of cryo-immunology.
Bibliographic Details
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know